Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $31.46 Average PT from Analysts

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $31.62.

Several analysts recently commented on the stock. Canaccord Genuity Group increased their target price on shares of Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. lifted their target price on Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Scotiabank boosted their target price on Travere Therapeutics from $27.00 to $32.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, February 12th. HC Wainwright lifted their price target on Travere Therapeutics from $18.00 to $22.00 and gave the stock a "buy" rating in a research note on Wednesday, January 15th. Finally, Citigroup upped their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Monday, February 24th.

Travere Therapeutics Stock Performance

TVTX traded up $1.01 during trading on Wednesday, reaching $14.50. 1,615,914 shares of the company were exchanged, compared to its average volume of 1,518,708. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The firm has a 50 day moving average of $19.60 and a 200 day moving average of $18.59. The stock has a market cap of $1.29 billion, a P/E ratio of -3.54 and a beta of 0.84. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $25.29.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. On average, sell-side analysts forecast that Travere Therapeutics will post -1.4 EPS for the current fiscal year.

Insider Transactions at Travere Therapeutics

In related news, SVP William E. Rote sold 5,200 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $23.53, for a total value of $122,356.00. Following the completion of the sale, the senior vice president now owns 98,519 shares of the company's stock, valued at approximately $2,318,152.07. The trade was a 5.01 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Sandra Calvin sold 54,244 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the transaction, the chief accounting officer now directly owns 54,410 shares in the company, valued at approximately $1,360,250. The trade was a 49.92 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 188,829 shares of company stock valued at $4,146,997. 4.06% of the stock is owned by insiders.

Institutional Investors Weigh In On Travere Therapeutics

A number of large investors have recently bought and sold shares of TVTX. The Manufacturers Life Insurance Company boosted its stake in shares of Travere Therapeutics by 61.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 47,045 shares of the company's stock worth $658,000 after acquiring an additional 17,931 shares in the last quarter. FMR LLC boosted its position in Travere Therapeutics by 27.5% during the third quarter. FMR LLC now owns 147,416 shares of the company's stock worth $2,062,000 after purchasing an additional 31,772 shares during the period. Two Sigma Advisers LP grew its holdings in Travere Therapeutics by 30.2% during the third quarter. Two Sigma Advisers LP now owns 720,400 shares of the company's stock valued at $10,078,000 after purchasing an additional 167,100 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Travere Therapeutics by 3.9% in the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company's stock valued at $24,222,000 after purchasing an additional 64,744 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Travere Therapeutics in the third quarter worth $301,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.